GlassScriptPhysician profile
Rhonda D Kobold
NPI 1356330526
$3,422.35
in general payments reported to CMS, 2019-2025
32 companies · $84.85 in 2025
The $84.85 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $540 · 2020: $347 · 2021: $227 · 2022: $1,271 · 2023: $687 · 2024: $265 · 2025: $84.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,037.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,037.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $584.13 | 2019-2025 | Acessa Provu System, Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Abbvie INC. | $531.90 | 2019-2023 | |
| Aspira Women'S Health INC | $389.60 | 2021-2023 | Ova1 |
| Novo Nordisk INC | $364.25 | 2019-2023 | Wegovy |
| Myovant Sciences INC. | $223.90 | 2022 | |
| Mayne Pharma Commercial LLC | $159.02 | 2021-2023 | |
| Organon LLC | $138.07 | 2021-2025 | Nexplanon, Jada System |
| Solventum Corporation | $125.46 | 2024 | Prevena, V.A.C.Ulta |
| Astrazeneca Pharmaceuticals LP | $111.79 | 2019 | |
| Astellas Pharma US INC | $96.40 | 2023 | Myrbetriq, Veozah |
| Merck Sharp & Dohme LLC | $87.40 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $82.87 | 2023 | Myfembree |
| Mylan Pharmaceuticals INC. | $47.32 | 2019-2020 | |
| Boston Scientific Corporation | $45.51 | 2019-2023 | Wavewriter Alpha Prime 16 |
| Exeltis, USA INC. | $45.19 | 2019-2023 | Slynd |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $40.17 | 2025 | Zurzuvae |
| Radius Health, INC. | $38.25 | 2019 | |
| Coopersurgical, INC. | $37.14 | 2022-2023 | |
| Therapeuticsmd, INC. | $36.63 | 2019-2020 | |
| Agile Therapeutics, INC. | $35.12 | 2022 | |
| Applied Medical Resources Corporation | $28.31 | 2023 | |
| Evofem Biosciences, INC. | $21.07 | 2022 | |
| Dexcom, INC. | $20.58 | 2025 | Dexcom G6 Transmitter |
| Sage Therapeutics, LLC | $17.57 | 2020 | |
| Smith+Nephew, INC. | $16.85 | 2023 | Pico 7 |
| Pfizer INC. | $16.16 | 2023 | |
| Allergan, INC. | $14.73 | 2020 | |
| Amag Pharmaceuticals, INC. | $14.60 | 2019 | |
| Vertical Pharmaceuticals, LLC | $14.51 | 2019 | |
| Daiichi Sankyo INC. | $13.79 | 2022 | |
| Avion Pharmaceuticals | $12.52 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rhonda Kobold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.